MA35153B1 - Immunoconjugués, compositions les contenant, et procédés de préparation et d'utilisation correspondants - Google Patents
Immunoconjugués, compositions les contenant, et procédés de préparation et d'utilisation correspondantsInfo
- Publication number
- MA35153B1 MA35153B1 MA36439A MA36439A MA35153B1 MA 35153 B1 MA35153 B1 MA 35153B1 MA 36439 A MA36439 A MA 36439A MA 36439 A MA36439 A MA 36439A MA 35153 B1 MA35153 B1 MA 35153B1
- Authority
- MA
- Morocco
- Prior art keywords
- immunoconjugates
- processes
- preparation
- compositions containing
- antibody
- Prior art date
Links
- 229940127121 immunoconjugate Drugs 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title 1
- 229910019142 PO4 Inorganic materials 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 239000012038 nucleophile Substances 0.000 abstract 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 1
- 239000010452 phosphate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6857—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from lung cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6859—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from liver or pancreas cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/58—[b]- or [c]-condensed
- C07D209/60—Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06086—Dipeptides with the first amino acid being basic
- C07K5/06095—Arg-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention concerne un immunoconjugué dans lequel un agent de formule (i) promédicamenté par du phosphate et se liant au petit sillon de l'adn est conjugué avec un anticorps ou un fragment se liant à l'antigène d'un anticorps. Dans la formule (i), x représente un groupe partant pouvant être déplacé par un nucléophile. L'invention concerne également des composés servant à préparer ces immunoconjugués et l'utilisation des immunoconjugués.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161490117P | 2011-05-26 | 2011-05-26 | |
PCT/US2012/039312 WO2012162482A1 (fr) | 2011-05-26 | 2012-05-24 | Immunoconjugués, compositions les contenant, et procédés de préparation et d'utilisation correspondants |
Publications (1)
Publication Number | Publication Date |
---|---|
MA35153B1 true MA35153B1 (fr) | 2014-06-02 |
Family
ID=46172969
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA36439A MA35153B1 (fr) | 2011-05-26 | 2013-11-15 | Immunoconjugués, compositions les contenant, et procédés de préparation et d'utilisation correspondants |
Country Status (22)
Country | Link |
---|---|
US (2) | US8852599B2 (fr) |
EP (1) | EP2714092B1 (fr) |
JP (2) | JP6105566B2 (fr) |
KR (1) | KR102070464B1 (fr) |
CN (1) | CN103561772B (fr) |
AR (1) | AR086568A1 (fr) |
AU (1) | AU2012258750B2 (fr) |
BR (1) | BR112013029764A2 (fr) |
CA (1) | CA2837327C (fr) |
CL (1) | CL2013003393A1 (fr) |
CO (1) | CO6831975A2 (fr) |
EA (1) | EA024844B1 (fr) |
ES (1) | ES2814798T3 (fr) |
IL (1) | IL229477A (fr) |
MA (1) | MA35153B1 (fr) |
MX (1) | MX336806B (fr) |
PE (1) | PE20141480A1 (fr) |
SG (1) | SG195011A1 (fr) |
TW (1) | TW201300401A (fr) |
UY (1) | UY34100A (fr) |
WO (1) | WO2012162482A1 (fr) |
ZA (2) | ZA201309669B (fr) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8680247B2 (en) | 2007-07-17 | 2014-03-25 | Medarex, L.L.C. | Monoclonal antibodies against glypican-3 |
WO2013093809A1 (fr) | 2011-12-23 | 2013-06-27 | Pfizer Inc. | Régions constantes d'anticorps modifiés pour conjugaison spécifique à un site, et leurs procédés et utilisations |
KR20150119848A (ko) | 2012-12-21 | 2015-10-26 | 바이오얼라이언스 씨.브이. | 친수성 자기-희생 링커 및 그것의 포합체 |
US10233249B2 (en) | 2013-03-19 | 2019-03-19 | Beijing Shenogen Pharma Group Ltd. | Antibodies and methods for treating estrogen receptor-associated diseases |
EP3613468A1 (fr) | 2013-05-02 | 2020-02-26 | Glykos Finland Oy | Conjugués de charge utile toxiques de glycoprotéine |
KR20160042080A (ko) | 2013-08-12 | 2016-04-18 | 제넨테크, 인크. | 1-(클로로메틸)-2,3-디히드로-1H-벤조[e]인돌 이량체 항체-약물 접합체 화합물, 및 사용 및 치료 방법 |
MX2016007578A (es) | 2013-12-16 | 2016-10-03 | Genentech Inc | Compuestos de conjugado anticuerpo-farmaco dimerico de 1-(clorometil)-2,3-dihidro-1h-benzo [e] indol, y metodos de uso y tratamiento. |
SG11201605437YA (en) * | 2014-01-27 | 2016-08-30 | Pfizer | Bifunctional cytotoxic agents |
MX371403B (es) | 2014-03-20 | 2020-01-29 | Bristol Myers Squibb Co | Moleculas de andamiaje a base de fibronectina estabilizada. |
ES2856927T3 (es) * | 2014-04-30 | 2021-09-28 | Pfizer | Conjugados de fármaco-anticuerpo anti-PTK7 |
JP2017528418A (ja) | 2014-06-20 | 2017-09-28 | バイオアライアンス コマンディテール フェンノートシャップ | 抗葉酸受容体アルファ(fra)抗体−薬物コンジュゲート及びその使用方法 |
CA2952865A1 (fr) * | 2014-06-20 | 2015-12-23 | Bioalliance C.V. | Conjugues anticorps anti-cd22-medicament et leurs methodes d'utilisation |
EP3160513B1 (fr) | 2014-06-30 | 2020-02-12 | Glykos Finland Oy | Dérivé de saccharide d'une charge utile toxique et conjugués d'anticorps de celui-ci |
GB201412658D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
CA2968357A1 (fr) | 2014-11-21 | 2016-05-26 | Bristol-Myers Squibb Company | Anticorps anti-cd73 et leurs utilisations |
DK3221346T3 (da) | 2014-11-21 | 2020-10-12 | Bristol Myers Squibb Co | Antistoffer omfattende modificerede konstante områder af tungkæden |
MX2017006530A (es) | 2014-11-25 | 2017-08-10 | Bristol Myers Squibb Co | Nuevos peptidos que se unen al ligando-1 de muerte programada (pd-l1) para formacion de imagen. |
JP2018510864A (ja) | 2015-03-10 | 2018-04-19 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | トランスグルタミナーゼによって結合可能な抗体およびそれによって製造される結合体 |
CA2923862C (fr) | 2015-03-20 | 2024-02-13 | Pfizer Inc. | Agents cytotoxiques bifonctionnels contenant le pharmacophore cti |
ES2936317T3 (es) | 2015-05-29 | 2023-03-16 | Bristol Myers Squibb Co | Anticuerpos contra OX40 y usos de los mismos |
US11077204B2 (en) | 2015-07-10 | 2021-08-03 | Byondis B.V. | Compositions comprising antibody-duocarmycin drug conjugates |
GB201601073D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies |
GB201601077D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibody molecule |
GB201601075D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies molecules |
JP6880001B2 (ja) | 2015-08-28 | 2021-06-02 | ヴェンタナ メディカル システムズ, インク. | ケージドハプテンを使用するホルマリン固定パラフィン包埋組織におけるタンパク質近接アッセイ |
CN108884147B (zh) | 2015-09-23 | 2024-02-27 | 百时美施贵宝公司 | 结合磷脂酰肌醇蛋白聚糖3的基于纤连蛋白的支架分子 |
AU2016355569B2 (en) | 2015-11-18 | 2020-01-02 | Merck Sharp & Dohme Llc | CTLA4 binders |
CA2949032A1 (fr) | 2015-11-30 | 2017-05-30 | Pfizer Inc. | Conjugues de medicaments anticorps her2 specifiques au site |
MX2018007479A (es) | 2015-12-21 | 2018-08-01 | Squibb Bristol Myers Co | Anticuerpos variantes para conjugacion especifica de sitio. |
MX2018008144A (es) | 2016-01-08 | 2018-11-09 | Bioalliance Cv | Anticuerpos tetravalentes anti ligando-1 de glicoproteina p-selectina (psgl-1) y usos de estos. |
WO2017152085A1 (fr) | 2016-03-04 | 2017-09-08 | Bristol-Myers Squibb Company | Polythérapie avec des anticorps anti-cd73 |
US20170326249A1 (en) | 2016-05-10 | 2017-11-16 | Bristol-Myers Squibb Company | Antibody-drug conjugate of an anti-glypican-3 antibody and a tubulysin analog, preparation and uses |
CN109641911B (zh) | 2016-08-19 | 2023-02-21 | 百时美施贵宝公司 | seco-环丙吡咯并吲哚化合物和其抗体-药物缀合物以及制备和使用方法 |
EP3486242B1 (fr) | 2016-08-31 | 2021-12-08 | Jiangsu Hengrui Medicine Co., Ltd. | Dérivé d'oxopicolinamide, son procédé de préparation et son utilisation pharmaceutique |
US20190218294A1 (en) | 2016-09-09 | 2019-07-18 | Bristol-Myers Squibb Company | Use of an anti-pd-1 antibody in combination with an anti-mesothelin antibody in cancer treatment |
WO2018064094A1 (fr) | 2016-09-28 | 2018-04-05 | Bristol-Myers Squibb Company | Synthèse énantiosélective de composés de pyrroloindole |
JP7039582B2 (ja) * | 2016-11-03 | 2022-03-22 | ブリストル-マイヤーズ スクイブ カンパニー | 活性化可能な抗ctla-4抗体およびその使用 |
AU2018219887B2 (en) | 2017-02-08 | 2024-08-15 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
SG11201907271PA (en) * | 2017-02-10 | 2019-09-27 | Dragonfly Therapeutics Inc | Proteins binding psma, nkg2d and cd16 |
CA3235295A1 (fr) | 2017-02-20 | 2018-08-23 | Dragonfly Therapeutics, Inc. | Proteines se liant a her2, nkg2d et cd16 |
EP3630833A1 (fr) | 2017-05-25 | 2020-04-08 | Bristol-Myers Squibb Company | Anticorps comprenant des régions constantes de chaîne lourde modifiées |
CN111094352A (zh) | 2017-08-25 | 2020-05-01 | 戊瑞治疗有限公司 | B7-h4抗体及其使用方法 |
US11364303B2 (en) | 2017-09-29 | 2022-06-21 | Pfizer Inc. | Cysteine engineered antibody drug conjugates |
CN108148137B (zh) * | 2017-12-29 | 2021-03-23 | 中国人民解放军第四军医大学 | 一种b7h4/1e10单克隆抗体及其应用 |
US11884733B2 (en) | 2018-02-08 | 2024-01-30 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the NKG2D receptor |
AU2019228600A1 (en) | 2018-03-02 | 2020-09-24 | Five Prime Therapeutics, Inc. | B7-H4 antibodies and methods of use thereof |
EP3887397A1 (fr) | 2018-11-28 | 2021-10-06 | Bristol-Myers Squibb Company | Anticorps comprenant des régions constantes de chaîne lourde modifiées |
ES2943474T3 (es) | 2018-11-30 | 2023-06-13 | Bristol Myers Squibb Co | Anticuerpo que comprende una extensión carboxiterminal de una cadena ligera que contiene glutamina, conjugados del mismo, y métodos y usos |
WO2020123425A2 (fr) | 2018-12-12 | 2020-06-18 | Bristol-Myers Squibb Company | Anticorps modifiés pour la conjugaison de la transglutaminase, conjugués associés, et méthodes et utilisations |
MX2021014960A (es) * | 2019-06-06 | 2022-03-04 | Shanghai Hansoh Biomedical Co Ltd | Conjugado de farmaco-anticuerpos anti-b7-h4 y uso medicinal del mismo. |
WO2021055306A1 (fr) | 2019-09-16 | 2021-03-25 | Bristol-Myers Squibb Company | Méthode de capture double d'analyse de conjugués anticorps-médicament |
JP2024504512A (ja) | 2020-12-21 | 2024-01-31 | コーネル・ユニバーシティー | ペプチド連結薬物送達系 |
JP2024501894A (ja) | 2021-01-04 | 2024-01-16 | メルサナ セラピューティクス インコーポレイテッド | B7h4ターゲティング抗体-薬物コンジュゲートおよびその使用方法 |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0527189A1 (fr) | 1990-04-25 | 1993-02-17 | PHARMACIA & UPJOHN COMPANY | Nouveaux analogues de cc-1065 |
US5686072A (en) * | 1992-06-17 | 1997-11-11 | Board Of Regents, The University Of Texas | Epitope-specific monoclonal antibodies and immunotoxins and uses thereof |
US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
US5659022A (en) | 1996-01-05 | 1997-08-19 | Epoch Pharmaceuticals, Inc. | Oligonucleotide-cyclopropapyrroloindole conjugates as sequence specific hybridization and crosslinking agents for nucleic acids |
KR100942863B1 (ko) | 1999-08-24 | 2010-02-17 | 메다렉스, 인코포레이티드 | 인간 씨티엘에이-4 항체 및 그의 용도 |
US6989452B2 (en) | 2001-05-31 | 2006-01-24 | Medarex, Inc. | Disulfide prodrugs and linkers and stabilizers useful therefor |
WO2003000201A2 (fr) | 2001-06-25 | 2003-01-03 | Drug Innovation & Design, Incorporated | Ciblage cellulaire faisant appel a la reconnaissance des formes exponentielle, compositions, procedes et applications anticancereuses |
EP1471938A4 (fr) | 2002-01-09 | 2008-03-05 | Medarex Inc | Anticorps monoclonaux humains contre cd30 |
US6756397B2 (en) | 2002-04-05 | 2004-06-29 | Immunogen, Inc. | Prodrugs of CC-1065 analogs |
RU2377252C2 (ru) | 2003-07-22 | 2009-12-27 | Шеринг Акциенгезельшафт | Rg1 антитела и их применение |
US7691962B2 (en) | 2004-05-19 | 2010-04-06 | Medarex, Inc. | Chemical linkers and conjugates thereof |
NZ550934A (en) | 2004-05-19 | 2010-05-28 | Medarex Inc | Chemical linkers and conjugates thereof |
BRPI0607796A2 (pt) | 2005-02-18 | 2009-06-13 | Medarex Inc | composto ou um sal farmaceuticamente aceitável do mesmo, processo para preparação e uso do mesmo, e, composição farmacêutica |
NZ556661A (en) | 2005-02-18 | 2010-10-29 | Medarex Inc | Human monoclonal antibodies to prostate specific membrance antigen (PSMA) |
NZ563193A (en) | 2005-05-09 | 2010-05-28 | Ono Pharmaceutical Co | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
EP1899379B1 (fr) | 2005-06-20 | 2018-04-11 | E. R. Squibb & Sons, L.L.C. | Anticorps cd19 et utilisations |
AU2006294663B2 (en) | 2005-09-26 | 2012-03-22 | Medarex, Inc. | Human monoclonal antibodies to CD70 |
US20080279868A1 (en) * | 2005-09-26 | 2008-11-13 | Medarex, Inc. | Antibody-Drug Conjugates and Methods of Use |
WO2007059404A2 (fr) | 2005-11-10 | 2007-05-24 | Medarex, Inc. | Composes et conjugues cytotoxiques |
NZ594466A (en) | 2005-12-08 | 2012-08-31 | Medarex Inc | Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies |
NZ568015A (en) | 2005-12-08 | 2012-03-30 | Medarex Inc | Human monoclonal antibodies to O8E |
JP5346589B2 (ja) | 2006-02-02 | 2013-11-20 | シンタルガ・ビーブイ | 水溶性cc−1065類似体及びその接合体 |
JP2010502221A (ja) | 2006-09-08 | 2010-01-28 | アンブルックス,インコーポレイテッド | 脊椎動物細胞による非天然アミノ酸の部位特異的組み込み |
JP5398538B2 (ja) | 2006-12-01 | 2014-01-29 | メダレックス・リミテッド・ライアビリティ・カンパニー | Cd22に結合するヒト抗体およびその使用 |
CL2007003622A1 (es) | 2006-12-13 | 2009-08-07 | Medarex Inc | Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales. |
CN101605906A (zh) * | 2006-12-14 | 2009-12-16 | 梅达雷克斯公司 | 结合cd70的人类抗体及其用途 |
AU2007333098A1 (en) * | 2006-12-14 | 2008-06-19 | Medarex, Inc. | Human antibodies that bind CD70 and uses thereof |
UY30776A1 (es) | 2006-12-21 | 2008-07-03 | Medarex Inc | Anticuerpos cd44 |
TWI412367B (zh) * | 2006-12-28 | 2013-10-21 | Medarex Llc | 化學鏈接劑與可裂解基質以及其之綴合物 |
US8664407B2 (en) | 2007-02-21 | 2014-03-04 | Medarex, LLC | Chemical linkers with single amino acids and conjugates thereof |
US8680247B2 (en) | 2007-07-17 | 2014-03-25 | Medarex, L.L.C. | Monoclonal antibodies against glypican-3 |
PL2195017T3 (pl) | 2007-10-01 | 2015-03-31 | Bristol Myers Squibb Co | Ludzkie antyciała, które wiążą mezotelinę i ich zastosowania |
EP2229187A2 (fr) | 2007-11-30 | 2010-09-22 | Bristol-Myers Squibb Company | Conjugués anticorps monoclonal-molécules partenaires dirigés contre la protéine tyrosine kinase 7 (ptk7) |
BRPI0819765A2 (pt) * | 2007-11-30 | 2015-05-05 | Bristol Myers Squibb Co | Conjugados de anticorpos anti-rg-1 |
TW200938224A (en) * | 2007-11-30 | 2009-09-16 | Medarex Inc | Anti-B7H4 monoclonal antibody-drug conjugate and methods of use |
-
2012
- 2012-05-22 US US13/477,219 patent/US8852599B2/en active Active
- 2012-05-24 AR ARP120101857A patent/AR086568A1/es unknown
- 2012-05-24 KR KR1020137033963A patent/KR102070464B1/ko active IP Right Grant
- 2012-05-24 EA EA201391754A patent/EA024844B1/ru not_active IP Right Cessation
- 2012-05-24 SG SG2013085048A patent/SG195011A1/en unknown
- 2012-05-24 CN CN201280025332.4A patent/CN103561772B/zh not_active Expired - Fee Related
- 2012-05-24 JP JP2014512101A patent/JP6105566B2/ja not_active Expired - Fee Related
- 2012-05-24 ES ES12724065T patent/ES2814798T3/es active Active
- 2012-05-24 EP EP12724065.3A patent/EP2714092B1/fr active Active
- 2012-05-24 WO PCT/US2012/039312 patent/WO2012162482A1/fr active Application Filing
- 2012-05-24 CA CA2837327A patent/CA2837327C/fr not_active Expired - Fee Related
- 2012-05-24 MX MX2013013402A patent/MX336806B/es active IP Right Grant
- 2012-05-24 BR BR112013029764A patent/BR112013029764A2/pt not_active Application Discontinuation
- 2012-05-24 AU AU2012258750A patent/AU2012258750B2/en not_active Ceased
- 2012-05-24 PE PE2013002713A patent/PE20141480A1/es not_active Application Discontinuation
- 2012-05-25 TW TW101118845A patent/TW201300401A/zh unknown
- 2012-05-25 UY UY0001034100A patent/UY34100A/es unknown
-
2013
- 2013-11-15 MA MA36439A patent/MA35153B1/fr unknown
- 2013-11-17 IL IL229477A patent/IL229477A/en active IP Right Grant
- 2013-11-26 CL CL2013003393A patent/CL2013003393A1/es unknown
- 2013-12-11 CO CO13289636A patent/CO6831975A2/es not_active Application Discontinuation
- 2013-12-20 ZA ZA2013/09669A patent/ZA201309669B/en unknown
-
2014
- 2014-08-21 ZA ZA2014/06168A patent/ZA201406168B/en unknown
- 2014-08-28 US US14/471,096 patent/US9186416B2/en active Active
-
2017
- 2017-02-02 JP JP2017017666A patent/JP6359133B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA35153B1 (fr) | Immunoconjugués, compositions les contenant, et procédés de préparation et d'utilisation correspondants | |
MA47447B1 (fr) | 2-hétéroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides pour le traitement du cancer | |
TNSN07398A1 (fr) | Anticorps contre la p-cadherine | |
MA30778B1 (fr) | Derives de sulfonamides servant d'agonistes adrenergique et d'antagonistes muscariniques | |
MA30784B1 (fr) | Derives phenyliques et utilisation de ceux-ci en tant qu'immunomodulateurs. | |
MA32615B1 (fr) | Inhibiteurs de cmet | |
MA34641B1 (fr) | Anticorps anti-il-23 | |
MA51204B1 (fr) | Formes pharmaceutiques comprenant un inhibiteur de la kallicréine plasmatique | |
MA32391B1 (fr) | Activateurs de la glucokinase | |
MA31502B1 (fr) | Anticorps anti-notch 1 specifiques a nrr et ses procedes d'utilisation | |
MA31027B1 (fr) | INHIBITEURS DE L'ACTIVITE Akt | |
MA31763B1 (fr) | Inhibiteurs de kinase de type polo | |
MA31519B1 (fr) | Compositions d'immunoglobulines lyophilisées et procédés de préparation | |
MA33178B1 (fr) | Pipéridines substituées comme antagonistes de ccr3 | |
MA35419B1 (fr) | Inhibiteurs de la tyrosine kinase de bruton | |
MA35422B1 (fr) | Imidazopyridazines amino-substituees | |
MA30289B1 (fr) | Dérivés d'amines | |
MA33208B1 (fr) | Anticorps anti-fgfr3 et procédés d'utilisation de ceux-ci | |
MA30765B1 (fr) | Derives innovants du thiophene | |
MA33402B1 (fr) | Compositions et procédés de ciblage de la proteine c3b de complément par des anticorps | |
MA34469B1 (fr) | Dérivés anticancéreux, préparation de ceux-ci et utilisation thérapeutique de ceux-ci | |
MA31158B1 (fr) | Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes | |
MA29411B1 (fr) | 1h-quinazoline -2,4-diones et leur utilisation en tant que ligands du recepteur ampa | |
MA47085B1 (fr) | Polymorphes | |
MA29839B1 (fr) | Derives de carboxamides servant d'antagonistes des recepteurs muscariniques |